Details of the Drug Reposition

General Information of This Drug (ID: DMLRIIP)

Drug Name	CMD-003 DMLRIIP

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lymphoma	DISN6V4S	2A80-2A86	Phase 2	[1]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01948180) Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)